Biosensors fends off Angiotech, Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Production and distribution of the Axxion drug-eluting stent continues in Europe after Biosensors prevails in a patent dispute brought by Angiotech and Boston Scientific. Biosensors' stent originally was cleared for sale in Europe in July 2005, but the firm was sued in December 2005. Angiotech and Boston Scientific claimed the device infringed a patent describing the use of paclitaxel and a polymeric coating on a stent. The news could be heartening to stent manufacturer Conor Medsystems, which is also embroiled in litigation in the Netherlands against Angiotech and Boston Scientific over the same patent (1"The Gray Sheet" Feb. 7, 2005, p. 7)...
You may also be interested in...
Taxus Companies Clash With Conor Over European Paclitaxel Patent
Boston Scientific and Angiotech Pharmaceuticals are attempting to block Conor Medsystems' use of clinical trial data that would support a European CE mark for the CoStar paclitaxel-eluting stent
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.